Immunovant, Inc. IMVT

33.30 (0.70) (2.06%) as of 25 Sep
Market cap
$7.1B
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

9.07 15.74 9.09 7.27
Net Debt/EBITDA
3.96 8.70 5.66 4.98
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.81 0.83 0.64 0.81
Capex/Depreciation
0.00 0.00 (0.08) 0.00
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.59) (0.51) (0.52) (0.61)
Cash per Share
3.01 5.48 4.95 3.88
Shareholders Equity per Share
2.99 5.43 4.67 3.58
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
2.99 5.43 4.67 3.58
Free Cash Flow
(102.51) (92.32) (95.07) (124.40)
Working Capital
510.29 976.68 844.40 734.08
Capital Expenditures
— — (0.01) —
Net Current Asset Value
510.29 976.68 844.40 734.08
Other line items
Quick Ratio
8.28 15.03 8.65 6.82
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.59) (0.51) (0.52) (0.61)
Capex per Share
0.00 0.00 0.00 0.00
Average Receivables
1.92 1.93 1.82 1.32
Average Payables
13.82 14.22 12.60 8.99
Average Assets
549.33 736.66 866.62 756.97
Average Common Equity
484.38 669.38 780.02 671.96
Capex to Sales
— — 0.00 —
Net Profit Margin
0.00% 0.00% 0.00% 0.00%

Fold the line items

Columns are period end dates